Investigational Drug Details
| Drug ID: | D440 |
| Drug Name: | Atrasentan |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB06199 |
| DrugBank Description: | Atrasentan is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists. It is a novel, selective endothelin A receptor antagonist (SERA). |
| PubChem ID: | 159594 |
| CasNo: | 173937-91-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C1=CC=C(OC)C=C1)C(O)=O)C1=CC2=C(OCO2)C=C1 |
| Structure: |
|
| InChiKey: | MOTJMGVDPWRKOC-QPVYNBJUSA-N |
| Molecular Weight: | 510.6218 |
| DrugBank Targets: | Endothelin-1 receptor |
| DrugBank MoA: | |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Investigated for use/treatment in prostate cancer and cancer/tumors (unspecified). |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1144 | NCT00596167 | COMPLETED | YES | 2007-09 | 2016-03-25 | Details | |
| L1157 | NCT03329196 | PHASE3 | COMPLETED | YES | 2017-10-30 | 2023-12-28 | Details |
| L1182 | NCT01672047 | UNKNOWN | NO | 2012-04 | 2012-08-30 | Details | |
| L1198 | NCT00410449 | COMPLETED | NO | 2001-05 | 2015-10-06 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|